Seemann; Gerhard

Patent Applications and Registrations

Patent applications and USPTO patent grants for Seemann; Gerhard.The latest application filed is for "monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof".

Company Profile

0.11.7

Seemann; Gerhard - Marburg DE
Seemann; Gerhard - Lollar DE
SEEMANN, GERHARD - MARBURG-ELNHAUSEN DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Chimeric antibody against tumor associated antigens and its use in diagnosing tumors Grant 7,662,383 - Bosslet , et al. February 16, 2	2010-02-16
Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof App 20090246132 - Bosslet; Klaus ; et al.	2009-10-01
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates Grant 7,241,595 - Kolar , et al. July 10, 2	2007-07-10
Fusion proteins for prodrug activation App 20060292139 - Gehrmann; Mathias ; et al.	2006-12-28
Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof App 20060159682 - Bosslet; Klaus ; et al.	2006-07-20
Fusion proteins for prodrug activation Grant 7,060,495 - Gehrmann , et al. June 13, 2	2006-06-13
Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof Grant 6,926,896 - Bosslet , et al. August 9, 2	2005-08-09
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates Grant 6,610,299 - Kolar , et al. August 26, 2	2003-08-26
Extension Of The Expression Of Transgenic Proteins By Immunomodulation App 20030082151 - SEEMANN, GERHARD ; et al.	2003-05-01
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates App 20030064482 - Kolar, Cenek ; et al.	2003-04-03
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates Grant 6,475,486 - Kolar , et al. November 5, 2	2002-11-05
Monoclonal Antibodies (mabs) Against Tumor-associated Antigens, The Preparation And Use Thereof App 20020068056 - BOSSLET, KLAUS ; et al.	2002-06-06
Fusion Proteins For Prodrug Activation App 20020068329 - GEHRMANN, MATHIAS ; et al.	2002-06-06
Tetravalent bispecific receptors, the preparation and use thereof Grant 5,959,083 - Bosslet , et al. Sept	1999-09-28
Monoclonal antibody against complexed and non-complexed complexing agents for removing heavy metals from aqueous solutions and for analysis Grant 5,907,034 - Bosslet , et al. May 25, 1	1999-05-25
Granulocyte-binding antibody constructs, their preparation and use Grant 5,645,817 - Seemann , et al. July 8, 1	1997-07-08
Bispecific and oligospecific mono-and oligovalent receptors, the preparation and use thereof Grant 5,591,828 - Bosslet , et al. J	1997-01-07
Glycosylated prodrugs, their method of preparation and their uses Grant 5,561,119 - Jacquesy , et al. October 1, 1	1996-10-01

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.